1. Medicine

Category Archives: Medicine

Watch Dogs Bad Blood Gameplay Walkthrough Part 7 – Bad Medicine (PS4 DLC) – Video

Posted on by


Watch Dogs Bad Blood Gameplay Walkthrough Part 7 - Bad Medicine (PS4 DLC)
Watch Dogs Bad Blood Gameplay Walkthrough Part 7 includes DLC Mission 6 of this Watch Dogs Bad Blood DLC Gameplay Walkthrough for PS4, Xbox One, PS3, Xbox 360 and PC in 1080p HD. This Watch...

By: theRadBrad

View post:

Watch Dogs Bad Blood Gameplay Walkthrough Part 7 - Bad Medicine (PS4 DLC) - Video

First mapping that reveals the molecular pathway for MDSC cancer progression

Posted on by

PUBLIC RELEASE DATE:

30-Sep-2014

Contact: Michael Petr michael.petr@insilicomedicine.com InSilico Medicine, Inc. @InSilicoMeds

Scientists from InSilico Medicine and its partners successfully established a visual mapping of the molecular pathway cancer progression originating from myeloid derived suppressor cells (MDSC). The damage and immune suppression the cells cause are not fully understood, however this is a major stepping stone in creating necessary transparency.

"MDSCs are elicited by tumor-derived factors from precursors present in hematopoietic organs such as the bone marrow and possibly spleen. This population of cells suppresses the activity of various types of immune cells and contributes to tumor progression by promoting tumor angiogenesis and metastasis. But the key transcriptional regulators of MDSC are still poorly defined. Alex and colleagues used bioinformatic tools to investigate the pathway interactome maps in colon and breast cancer models. Several proliferation and invasion-related pathways were identified in infiltrating MDSC. It opens a door to new therapy targeting MDSC in these diseases. " says Qingsong Zhu, COO of InSilico Medicine, Inc.

###

More on the study can be found here: http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=2489&path%5B%5D=4445.

About InSilico Medicine

InSilico Medicine was founded in early 2014 and has since developed the OncoFinder and Geroscope. It is a company dedicated to finding novel solutions towards aging and age-related diseases using advances in genomics and big data analysis. Through internal expertise and extensive collaborations with brilliant scientists, institutions, and highly credible pharmaceutical companies, InSilico Medicine seeks to revolutionize personalized science and drug discovery. More can be read about InSilico Medicine, Inc. at http://www.insilicomedicine.com.

More:

First mapping that reveals the molecular pathway for MDSC cancer progression

About the Turning the Tide Against Cancer Co-Conveners: Personalized Medicine Coalition – Video

Posted on by


About the Turning the Tide Against Cancer Co-Conveners: Personalized Medicine Coalition
The Personalized Medicine Coalition (PMC) is an education and advocacy organization that is focused on encouraging innovation in personalized medicine. Learn more about their role as a ...

By: TTTACancer

Follow this link:

About the Turning the Tide Against Cancer Co-Conveners: Personalized Medicine Coalition - Video

Daily Dose of Aspirin May Cut Prostate Cancer Risk: Study

Posted on by

Men who take a daily dose of aspirin or similar anti-inflammatory medicine may also reduce their risk of developing prostate cancer, researchers said.

The study, presented today at an American Association for Cancer Research meeting, found that men who regularly used anti-inflammatory pain pills had a 13 percent lower risk of prostate cancer and 17 percent fewer dangerous, high-grade tumors. A second study suggested the mechanism responsible for preventing the tumors could be the medicines ability to block production of a hormone that spurs cancer growth.

Low-dose aspirin is taken by millions of Americans to prevent heart attacks and strokes, said Pierre Massion, a professor of medicine and cancer biology at Vanderbilt University School of Medicine in Nashville who worked on the research. It has been shown to prevent colon cancer. What we are saying is that the benefit of aspirin even at low doses could also help other cancers, including lung, breast and prostate.

While promising results have been shown in studies of other tumor types, people generally dont take aspirin to prevent cancer or slow its growth. One obstacle was that researchers didnt know how aspirin worked on tumors. The new findings help answer those questions, Massion said in a telephone interview.

We found the mechanism to explain how low-dose aspirin can eventually decrease the incidence of new cancers after you have taken it for five years or more, he said. It can also explain why people who are taking aspirin after being diagnosed have a lower risk of dying of their metastases.

Massions laboratory study showed aspirin inhibited production of Cox-2, which then reduced levels of a prostaglandin called PGE2 that spurs cancer metastases. The findings mean aspirin doesnt only prevent blood platelets from sticking together, the primary way it helps reduce heart attacks. At the cellular level, it can also block Cox-2 in cancer, he said.

Studies to prevent prostate and other cancers with Merck & Co.s Vioxx, a pain medicine that blocked Cox-2, were halted after the drug was pulled from the market because of its heart disease risks. Pfizer Inc. hasnt developed its Cox-2 inhibitor Celebrex for prostate cancer, though it is approved to treat a rare condition where intestinal polyps can lead to colon cancer.

Adriana Vidal, an assistant professor at Duke University School of Medicine and the lead author of the study that looked at prostate cancer rates, said more research is needed. The drugs have side effects, including gastrointestinal bleeding, which have to be weighed against the benefits, she said. The study was based on the patients self-reported use of aspirin and pain medicine.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Drew Armstrong, Andrew Pollack

Original post:

Daily Dose of Aspirin May Cut Prostate Cancer Risk: Study

Combating Ageing: from Biotech Printing to Regenerative Medicine

Posted on by

Increased budgets and higher financial returns in the battle to stave off the ageing process mean that Regenerative Medicine is becoming the new darling of the US transhumanist movement.

The US population is ageing. In 2030, 20% of all US Americans will be over 65 years old. Billionaire Peter Thiel, the founder of Paypal and a key Silicon Valley player, strongly believes in the need to support work on regenerative biology and has donated millions of dollars to the SENS (Strategies for Engineered Negligible Senescence) Foundation established by the controversial English biologist Aubrey de Grey. Meanwhile the anti-ageing biotechnology market has been seeing huge growth, both in terms of rising turnover currently amounting to some $2 billion according to investment and advisory firm Proteus Venture Partners and the enthusiasm it has aroused among many scientists, manufacturers and politicians. However, reactions in the scientific community have been mixed, with some experts expressing scepticism about anti-ageing efforts. Given our current ignorance of the subject, the promises made for this new approach to medicine are at best speculation.

In 2013 Google dipped its toe into the waters of the anti-ageing therapy business when it founded the California Life Company (Calico), an independent biotech R&D firm whose stated aim is to extend the natural lifespan of human beings. However, research in this field has been somewhat hampered by popular association with upstart companies offering rather fanciful cryopreservation services (i.e. storing the bodies of recently deceased people at very low temperatures in the hope of future cure and resuscitation) to people about to die. Thus the image of the relatively new field of Regenerative Medicine has been tarnished among the scientific community by the rise of a brash anti-death industry. It was probably largely to counter this negative image that radiologist and investor Joon Yun recently inaugurated the Palo Alto Longevity Prize, a $1 million life science competition dedicated to ending ageing in humans. Joon Yun explains that the purpose of the competition is to provide a way to urge researchers to hack the ageing code, taking up the torch from James Watson and Francis Crick, the UK-based scientists who first revealed the three-dimensional double helix structure of the DNA molecule. In fact, back in 2011, when the anti-ageing ecosystem was far less advanced than it is today, the United States Congress got into step with the new thinking when it passed the The Regenerative Medicine Promotion Act, designed to provide funding for this new avenue of research and foster its development. However, the scientific community has not been unanimously behind this drive and much controversy is raging over current anti-ageing initiatives. Criticism usually centres on the over-optimistic tone of many researchers backed by the SENS Foundation, which some experts say is not justified by actual progress to date.

Much current research into the ageing process takes a rather utilitarian approach to mortality defining ageing as the gradual deterioration of an organism and arguing that it should be perfectly possible to make repairs fast enough to keep ahead of the ongoing decline. The general hypothesis is that if death is the result of organism deterioration then it follows that repairing the deteriorating cells should delay death. However, the anti-ageing battle is being fought on two separate fronts, in terms of the basic objectives and means applied. On the one hand there are the well-established biotech processes, including 3D bio-printers, ranging from the CRISPR gene editing system to the Regenovo cell-printer, which already enable living organisms, from sequenced genomes to complete organs, to be manufactured. The journal Rejuvenation Research first appeared as long ago as 1998, spearheaded by Editor-in-Chief Aubrey de Grey, whose career has ranged from computer programming to applied biology. Aubrey de Grey also co-founded The Methuselah Foundation in 2003, before setting up SENS in 2009. Their credo is that bio-medicine must be rooted in the living organisms metabolism in order to treat the pathological condition, the aim being to act specifically to repair the damage done to the organism by using rejuvenating engineering techniques. Aubrey de Grey and his colleagues argue that the answer to ageing is Regenerative Medicine at the cellular level, providing appropriate treatment for the cells whether they are mutating to become cancerous or simply ageing.

See more here:

Combating Ageing: from Biotech Printing to Regenerative Medicine

Focus on Your Health: Performing Arts Medicine, with Dr. Jennifer Yang – Video

Posted on by


Focus on Your Health: Performing Arts Medicine, with Dr. Jennifer Yang
Focus on Your Health is a weekly program on the K-Jazz Radio Network in northern and western Arizona. This edition features Dr. Jennifer Yang, who specializes in physical medicine and rehabilitatio...

By: T. G LaFredo

Go here to read the rest:

Focus on Your Health: Performing Arts Medicine, with Dr. Jennifer Yang - Video


  1. Medicine